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Transcatheter Aortic Valve Replacement with a New Self-expanding
Percutaneous Heart Valve and Motorized Delivery System
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Jonathon Leipsic1, Stefan Toggweiler1, Melanie Freeman1, Alex Willson1,
John Webb1
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2Asklepios Klinik St. Georg - University of Hamburg, Hamburg, Germany
Background: Refining transcatheter aortic valve replacement with newly designed
bioprosthesis and delivery systems is anticipated to reduce the risk of complications and
enhance ease of prosthesis implantation. We report the first-in-human experience and
short- and mid-term clinical outcomes with a new self-expanding transcatheter heart valve
and motorized delivery system.
Methods: The CENTERA valve (Edwards Lifesciences Inc., CA, USA) was implanted
in 15 patients with symptomatic severe aortic stenosis via percutaneous femoral or axillary
arterial access. Patients underwent transthoracic echocardiography and multidetector comput-
erized tomography before and after valve implantation. Clinical and echocardiographic follow
up was obtained at 30 days and for the initial 10 patients after one year. Outcomes were
reported according to the Valve Academic Research Consortium guidelines.
Results: All 15 device implants were successful. Aortic valve area increased from 0.7
0.1 cm2 to 1.6  0.4 cm2 post procedure (p  0.01) and 1.8  0.3 cm2 at one-year
follow-up. Mean trans-aortic gradient decreased from 36.3  14.2 mmHg to 10.6  5.4
mmHg post-procedure (p  0.001) and to 10.8  4.1 mmHg at one year follow-up. All
patients were in NYHA class I (25%) or II (75%) at one-year follow-up and only one
patient had more than mild paravalvular regurgitation at one-year follow-up. Four patients
(27%) received a new permanent pacemaker. Survival was 87% at 30 days and 80% at
one year. None of the deaths were valve related.
Conclusions: Transcatheter aortic valve replacement with the CENTERA transcatheter
heart valve and motorized delivery system is feasible and leads to excellent short- and
mid-term clinical and hemodynamic outcomes.
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Background: Permanent pacemaker Implantation (PP) following high degree atrio-
ventricular block is a frequent complication after Transcatheter Aortic Valve Implantation
(TAVI) by using self expanding bioprothesis (SEB) system. Recent improvements of SEB
from CoreValve Device (CD) to Accutrack CoreValve Device (ACD) have aimed to
allow easier delivery and also expected to reduce the PP rate. However, the clinical
outcome of PP occurrence and differences of PP rate between MCD and ACD after TAVI
remains unclear.
Methods: A total of 958 patients (82	7 years; female: 49%) with severe symptomatic
aortic stenosis were selected SEB between January 2010 and October 2011 in 33 centers
of the FRANCE 2 Registry. The current study investigated 1) the incidence of PP rate
according to the differences of 2 devices and 2) the midterm clinical outcome of PP
occurrence after TAVI.
Results: Procedural success rate was 96.9% and PP rate was 22.4% in overall population.
CD and ACD were implanted in 54.5% (n522) and 41.5% (n436) of patients,
respectively. There was no significant differences of PP rate between CD and ACD
(21.6% vs. 23.4%, p0.52). During the mean follow-up of 242	179 days, the PP
occurrence was not associated with increasing all cause mortality when compared with
non PP occurrence 14.4 % Vs 13.2 % (p0.33).
Conclusions: PP remains frequent after TAVI with SEB and device improvement failed
to show an impact on PP implantation rate. Overall mortality was not impacted by PP.
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Impact of experience on TAVI outcome a propensity matched analysis from
the PRAGMATIC Plus Initiative
Nicolas Van Mieghem1
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Background: Not much is known about the impact of the mounting clinical experience
and technological refinements on clinical endpoints after TAVI.
Methods: We retrospectively analyzed 793 consecutive TF-TAVI patients from 4
European centers and evaluated experience in three propensity score matched cohorts
subcategorized based on enrollment date.
Results: Three propensity score matched cohorts of 214 TF-TAVI patients were
identified. With mounting experience and moving from the initial to the last cohort,
all-cause 30-day mortality trended to be lower (7.0% in T1 vs. 3.7% in T3, p 0.16) but
with improved 1-year survival (79% vs. 86%, p  0.016). Over time there were
significantly less major vascular complications (15% vs. 7.9%, p  0.023), life
threatening (17.8% vs. 7.9%, p 0.003) and major bleedings (22.4% vs. 12.1%, p 
0.007). Major vascular complications and life-threatening bleedings due to closure device
failure decreased significantly (9.2% vs. 3.1%, p  0.01 and 5.7% vs. 1 %, p  0.01
respectively).The combined safety endpoint dropped from 31.3% in T1 to 17.8% in T3
(p  0.001). By multivariable analysis (including adjustment for arterial sheath size) the
last cohort as compared to the initial cohort was associated with significant reductions in
30-day mortality (OR 0.35, 95% CI 0.12 – 0.96), stage 3 AKI (OR 0.12, 95% CI 0.29 –
0.93) and the combined safety endpoint (OR 0.52, 95% CI 0.29 – 0.93).
Conclusions: Growing TAVI experience results in significant reductions in major
vascular complications, life threatening bleedings and the combined clinical safety
endpoint and improved 1-year survival.
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Background: In transcatheter aortic valve implantation (TAVI), short term mortality
closely relates to life threatening procedural complications. Veno-arterial extracorporeal
membrane oxygenation (vaECMO) can be used to stabilize the patient in emergency
situations. However, for the prophylactic use of ECMO in very high risk patients
undergoing TAVI there is no experience. We report our center’s experience using
vaECMO in TAVI.
Methods: From January 2009 to August 2011, we performed 131 TAVI. Emergency
vaECMO was required in 8 cases (7%): ventricular perforation (n3), hemodynamic
instability/ cardiogenic shock (n4), hemodynamic deterioration due to ventricular
tachycardia (n1). From August 2011 on, during 83 procedures, prophylactic vaECMO
was systematically used in very high risk patients (n9, 11%) and emergency vaECMO
in one case (1%) due to ventricular perforation.
Results: Median logistic EuroScore in prophylactic vaECMO patients was considerably
higher compared to the remaining TAVI population (30% vs. 15%, p0.0003) while
logistic EuroScore of patients with emergency vaECMO was comparable (18% vs. 15%,
p0.08). Comparing prophylactic to emergency vaECMO, procedural success, proce-
dural related death, and 30-day mortality were 78% vs. 100% (p0.5), 33% vs. 0%
(p0.2) and 44% vs. 0% (p0.08), respectively. Major vascular complications and rate
of life threatening bleeding did not differ in both groups (11% vs. 11%, p0.99 and 11%
vs. 33%, p0.6) and were not vaECMO related.
Conclusions: Life-threatening complications during TAVI can be managed using
emergency vaECMO but mortality remains high. Systematic use of prophylactic
vaECMO in very high risk patients is safe and might be advocated in selected high risk
patients.
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Safety and Efficacy of 14Fr Balloon Expandable Sheath for Trans-catheter
Aortic Valve Implantation (TAVI)
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Background: The aim of this study is to show access site complication and success rate
in trans-catheter aortic valve implantation (TAVI) with 14Fr balloon expandable sheath
which is expanded to 19Fr in artery by comparing to those with standard 18Fr sheath.
Methods: From 106 consecutive patients who underwent TAVI, patients who had
subclavian (n  4) or trans direct aortic access (n  2) were excluded. Remaining 100
patients who underwent TAVI through femoral access were included in the study. Whole
sample was divided into 2 groups: standard18Fr (n  82) and 14Fr (n  18) balloon
expandable sheath group. Successful TAVI was defined as optimal positioning of a stent
valve with hemodynamical stability without additional valve. Access site complication
was defined as bleeding/hematoma which needed blood transfusion and vascular injury
including dissection, perforation, AV fistula and pseudoanuerysm which needed un-
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